Please share your phone number so we can contact you to learn about your health complaint.
Cyramza (Ramucirumab) is a modern targeted therapy used in the treatment of several cancers, including gastric cancer, colorectal cancer, and non-small cell lung cancer (NSCLC). It belongs to the class of angiogenesis inhibitors.
Cyramza is a monoclonal antibody that specifically blocks the VEGFR-2 receptor, which plays a central role in the formation of new blood vessels that tumors need for growth and survival. By inhibiting this pathway, Cyramza helps slow down or stop tumor progression.
Advanced gastric or gastroesophageal junction cancer after chemotherapy failure.
Colorectal cancer, often combined with other drugs such as FOLFIRI.
Non-small cell lung cancer (NSCLC) as a second-line treatment.
Sometimes used for hepatocellular carcinoma (HCC).
Cyramza is given as an intravenous infusion in a hospital setting.
The dosage is determined by patient’s weight and cancer type.
Usually administered once every two weeks or as per treatment protocol.
High blood pressure.
Fatigue and weakness.
Loss of appetite and weight loss.
Gastrointestinal bleeding or ulcers (rare).
Infusion-related reactions.
Cyramza in Egypt is available in specialized oncology centers. The price is relatively high, as it is a biologic therapy, and often requires insurance or special medical programs.
Cyramza (Ramucirumab) is an important targeted therapy option for patients with advanced gastric, colorectal, or lung cancer, especially when standard chemotherapy fails.
The medical information provided about Cyramza (Ramucirumab) is for educational purposes only and should not replace professional medical advice. Always consult your doctor before starting or stopping any treatment.
If you want to learn more about Cyramza in Egypt or book a consultation with an oncology specialist, contact Macrocare today for:
Access to treatment centers.
Expert consultation with oncologists.
Comprehensive treatment support.